EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Role of M. leprae Hsp65 Protein and Peptides in the Pathogenesis of Uveitis

Alessandra Gonçalves Commodaro, Eliana Blini Marengo, Jean Pierre S. Peron, Wesley Brandao, Christina Arslanian, Robson Lopes Melo, Estevam J. Baldon, Rubens Belfort, Osvaldo Augusto Sant'Anna, Luiz Vicente Rizzo

Autoimmune Diseases · 2012

DOI: 10.1155/2012/197648 ↗
AbstractBibliografische Angaben

Abstract

Experimental autoimmune uveitis (EAU) is a well established model for immune-mediated organ-specific disease. Our group has recently shown that the M. leprae Hsp65 aggravated the uveitis in mice; in the present study, we evaluated the action of M. leprae K 409 A mutant protein and the synthetic peptides Leader pep and K 409 A pep (covering amino acids residues 352–371 of WT and K 409 A proteins of M. leprae Hsp65, resp.) on the pathogenesis of EAU. Mice received the 161–180 IRBP peptide and B. pertussis toxin followed by the intraperitoneal inoculation of K 409 A protein or the Leader pep or K 409 A pep. The Leader pep aggravated the disease, but mice receiving the K 409 A pep did not develop the disease and presented an increase in IL-10 levels by spleen cells and a decrease in the percentage of CD4+ IFN- γ + T cells. Moreover, animals receiving the Leader pep presented the highest scores of the disease associated with increase percentage of CD4+ IFN- γ + T cells. These results would contribute to understanding of the pathogenesis of EAU and support the concept that immune responses to Hsp are of potential importance in exacerbating, perpetuating, or even controlling organ-restricted autoimmune diseases, and it is discussed the irreversibility of autoimmune syndromes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →